Evidence map›Paper›PMID 29969451›Full record

ArticlePloS one2018

Activation of Th2 cells downregulates CRTh2 through an NFAT1 mediated mechanism.

Emily MacLean Scott, Lauren A Solomon, Courtney Davidson, Jessica Storie, Nami Shrestha Palikhe, Lisa Cameron

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Coactosin-Like Protein Reduces Prostaglandin DAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Emily MacLean ScottPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CANADA.
Lauren A SolomonDepartment of Pathology and Laboratory Medicine, Western University, London, Ontario, CANADA.
Courtney DavidsonPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CANADA.
Jessica StoriePulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CANADA.
Nami Shrestha PalikhePulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CANADA.
Lisa CameronPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CANADA.ORCID 0000-0002-2108-8414
University of Alberta · CAWestern University · CA

Funding

Canadian Institute of Health Research 233605Canadian Institute of Health Research MOP111267
6 · The paper itself

Abstract

CRTh2 (encoded by PTGDR2) is a G-protein coupled receptor expressed by Th2 cells as well as eosinophils, basophils and innate lymphoid cells (ILC)2s. Activation of CRTh2, by its ligand prostaglandin (PG)D2, mediates production of type 2 cytokines (IL-4, IL-5 and IL-13), chemotaxis and inhibition of apoptosis. As such, the PGD2-CRTh2 pathway is considered important to the development and maintenance of allergic inflammation. Expression of CRTh2 is mediated by the transcription factor GATA3 during Th2 cell differentiation and within ILC2s. Other than this, relatively little is known regarding the cellular and molecular mechanisms regulating expression of CRTh2. Here, we show using primary human Th2 cells that activation (24hrs) through TCR crosslinking (αCD3/αCD28) reduced expression of both mRNA and surface levels of CRTh2 assessed by flow cytometry and qRT-PCR. This effect took more than 4 hours and expression was recovered following removal of activation. EMSA analysis revealed that GATA3 and NFAT1 can bind independently to overlapping sites within a CRTh2 promoter probe. NFAT1 over-expression resulted in loss of GATA3-mediated CRTh2 promoter activity, while inhibition of NFAT using a peptide inhibitor (VIVIT) coincided with recovery of CRTh2 expression. Collectively these data indicate that expression of CRTh2 is regulated through the competitive action of GATA3 and NFAT1. Though prolonged activation led to NFAT1-mediated downregulation, CRTh2 was re-expressed when stimulus was removed suggesting this is a dynamic mechanism and may play a role in PGD2-CRTh2 mediated allergic inflammation.

Indexed as

Antibodies, MonoclonalBase SequenceBinding, CompetitiveBinding SitesCD28 AntigensCD3 ComplexGATA3 Transcription FactorGene Expression RegulationHumansJurkat CellsLymphocyte ActivationNFATC Transcription FactorsPrimary Cell CulturePromoter Regions, GeneticProstaglandin D2Protein BindingAntibodies, MonoclonalCD28 AntigensCD3 ComplexGATA3 protein, humanGATA3 Transcription FactorNFATC2 protein, humanNFATC Transcription FactorsProstaglandin D2prostaglandin D2 receptorReceptors, ImmunologicReceptors, Prostaglandin

Identifiers

PMID29969451
PMCPMC6029763
OpenAlexW2809971493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.